Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation

Cancer statistics, 1999

Sarah Landis, Thomas S. Murray, S. Bolden et al. · CA A Cancer Journal for Clinicians · 1999 · 3.1K citations · Full text

Medicine, Biostatistics, Oncology +17

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

Patrick J. Loehrer, Lawrence H. Einhorn, Paul Elson et al. · Journal of Clinical Oncology · 1992 · 987 citations

Medicine, Oncology, Pharmacology +12

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

P M O'Connor, Joany Jackman, I Bae et al. · PubMed · 1997 · 882 citations

Medicine, Cancer Biology, Molecular Biology +15

Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer

David Esrig, Donald A. Elmajian, Susan Groshen et al. · New England Journal of Medicine · 1994 · 808 citations · Full text

Medicine, Oncology, Pathology +16

The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

Edmund A. Gehan · Journal of Chronic Diseases · 1961 · 670 citations

Medicine, Oncology, Pharmacology +3